First-In-DOg HISTotripsy for Intracranial Tumors Trial: The FIDOHIST Study

dc.contributor.authorVezza, Christinaen
dc.contributor.authorRuger, Laurenen
dc.contributor.authorLangman, Mayaen
dc.contributor.authorVickers, Ellianaen
dc.contributor.authorPrada, Francescoen
dc.contributor.authorSukovich, Jonathanen
dc.contributor.authorHall, Timothyen
dc.contributor.authorXu, Zhenen
dc.contributor.authorParker, Rell L.en
dc.contributor.authorVlaisavljevich, Elien
dc.contributor.authorRossmeisl, John H.en
dc.date.accessioned2025-01-31T14:22:07Zen
dc.date.available2025-01-31T14:22:07Zen
dc.date.issued2024-10-17en
dc.description.abstractObjective: Brain tumors represent some of the most treatment refractory cancers, and there is a clinical need for additional treatments for these tumors. Domesticated dogs are the only other mammalian species which commonly develop spontaneous brain tumors, making them an ideal model for investigating novel therapies. Histotripsy is a non-thermal ultrasonic ablation method that emulsifies tissue through acoustic cavitation. The primary objectives of this prospective study were to assess the feasibility and safety of histotripsy to ablate naturally occurring canine brain tumors. Secondary endpoints included characterization of magnetic resonance imaging (MRI) responses to histotripsy treatment, and exploratory immunogenomic tumor response analyses. Methods: The study design utilized a treat and resect paradigm, where tumors were approached using craniotomy, partially ablated with histotripsy delivered through the cranial defect, imaged with MRI, and then resected. Dogs were evaluated with clinical, brain MRI, immunopathologic, and genomic examinations before treatment, intraoperatively, and 1, 14, and 42 days post-treatment. Here we report the results of the three dogs with meningiomas, all of which were treated with a custom eight element 1 MHz histotripsy transducer at a pulse repetition frequency of 100 Hz and a treatment dosage of 400 pulses/point. Results: Histotripsy was successfully delivered to all dogs, resulting in histopathologic evidence of ablations that were sharply demarcated from untreated tumor, with measured treatments approximating planned volumes in 2/3 dogs. One dog experienced an adverse event consisting of transient cerebral edema that was possibly attributable to histotripsy. Histotripsy ablations could be grossly visualized and identified on MRI, with features consistent with hemorrhage and necrosis. Significant expression or upregulation of the damage associated molecular pattern HMGB1, cytokine-cytokine receptor interaction, and NF-κb signaling pathways were observed in histotripsy treated tumors. Conclusion: Ablation of canine meningiomas with histotripsy through an open cranial window was feasible and clinically well tolerated.en
dc.description.sponsorshipAuthor Lauren Ruger was supported by the Virginia Tech Institute for Critical Technology and Applied Science (ICTAS) Doctoral Scholars program throughout the duration of this work. Author Rell Parker is an iTHRIV Scholar. The iTHRIV Scholars Program is supported in part by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Numbers UL1TR003015 and KL2TR003016.en
dc.description.versionPublished versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.doihttps://doi.org/10.1177/15330338241285158en
dc.identifier.urihttps://hdl.handle.net/10919/124454en
dc.identifier.volume23en
dc.language.isoenen
dc.publisherSAGE Publicationsen
dc.rightsCreative Commons Attribution-NonCommercial 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/en
dc.subjectcanineen
dc.subjectbrain tumoren
dc.subjectfocused ultrasounden
dc.subjecthistotripsyen
dc.subjectmeningiomaen
dc.subjecttumor ablationen
dc.titleFirst-In-DOg HISTotripsy for Intracranial Tumors Trial: The FIDOHIST Studyen
dc.title.serialTechnology in Cancer Research & Treatmenten
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
vezza-et-al-2024-first-in-dog-study.pdf
Size:
3.18 MB
Format:
Adobe Portable Document Format
Description:
Published version
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.5 KB
Format:
Item-specific license agreed upon to submission
Description: